9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Condition Biphasic Mesothelioma|Epithelioid Mesothelioma|Peritoneal Malignant Mesothelioma|Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Pleural Sarcomatoid Mesothelioma|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Sarcomatoid Mesothelioma Estimated Enrollment: 65 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: IRB14-1381|NCI-2015-00348|P30CA014599 Study First Received: March 13, 2015 Last Updated: November 14, 2016 Estimated Primary Completion Date: March 2018 Primary Outcome Measures: Ability of PD-L1 to predict response|Overall survival (OS)|Progression free survival (PFS)|Disease control rate (CR + PR + SD) Sponsors and Collaborators: University of Chicago|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02399371...

Continue reading

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Condition Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Malignant Solid Neoplasm|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pleural Mesothelioma|Thymoma|Unresectable Solid Neoplasm Estimated Enrollment: 58 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: NCI-2015-00127|PHI-76|9837|P30CA033572|UM1CA186689|UM1CA186705|UM1CA186717|ZIABC011078 Study First Received: August 27, 2015 Last Updated: March 23, 2017 Estimated Primary Completion...

Continue reading

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Condition Advanced Pleural Malignant Mesothelioma|HLA-A*0201 Positive Cells Present|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pleural Mesothelioma Estimated Enrollment: 20 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2727.00|NCI-2015-00329|2727|P30CA015704 Study First Received: March 31, 2015 Last Updated: January 4, 2017 Estimated Primary Completion Date: June 2017 Primary Outcome Measures: Evidence and nature of toxicity based on the National Cancer Institute Common Terminology Criteria for Adverse Events version...

Continue reading

Four Versus Six Cycles of Pemetrexed/Platinum for MPM

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 70 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: Meso-01 Study First Received: July 10, 2015 Last Updated: July 13, 2015 Estimated Primary Completion Date: June 2016 Primary Outcome Measures: Progression free survival|Overall survival Sponsors and Collaborators: Ain Shams University Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02497053...

Continue reading

Short Neoadjuvant Hemithoracic IMRT for MPM

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 100 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: UHN REB 08-0106-C Study First Received: November 21, 2008 Last Updated: August 30, 2016 Estimated Primary Completion Date: July 2017 Primary Outcome Measures: The primary outcome for the study will be the proportion of patients treated as per protocol without treatment related mortality.|To evaluate: acute and late morbidity related to treatment; local & distant recurrence, disease free & overall survival; identify factors/parameters associated with increased risk of treatment morbidity Sponsors and Collaborators: University Health Network, Toronto Result Received: No...

Continue reading

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Condition To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy Estimated Enrollment: 30 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: ONCOS C719|2015-005143-13 Study First Received: July 13, 2016 Last Updated: February 9, 2017 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability|To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor...

Continue reading

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

Condition Gastric Cancers Estimated Enrollment: 1000 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 16294A Study First Received: August 20, 2010 Last Updated: July 20, 2016 Estimated Primary Completion Date: October 2017 Primary Outcome Measures: Collect and store blood samples|create a database for the collected tissue|To create tissue microarrays for each gastrointestinal cancer subtype Sponsors and Collaborators: University of Chicago Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01416714...

Continue reading

Staging Procedures to Diagnose Malignant Pleural Mesothelioma

Condition Mesothelioma|Solitary Fibrous Tumor of the Pleura Estimated Enrollment: 200 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: 15-007647 Study First Received: November 20, 2015 Last Updated: December 19, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Accuracy of surgical staging versus imaging procedures based on surgical findings. Sponsors and Collaborators: Mayo Clinic Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02648763...

Continue reading

Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma

Condition Mesothelioma|Solitary Fibrous Tumor of the Pleura Estimated Enrollment: 200 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: 15-007644 Study First Received: November 20, 2015 Last Updated: December 19, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Survival status upon review of patient records every 6 months Sponsors and Collaborators: Mayo Clinic Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02613299...

Continue reading

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Condition Mesothelioma|Solitary Fibrous Tumor of the Pleura Estimated Enrollment: 200 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: 15-007645 Study First Received: November 20, 2015 Last Updated: December 19, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Survival status upon review of patients every 6 months|Progression free survival as evidenced by CT scan review Sponsors and Collaborators: Mayo Clinic Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02613312...

Continue reading